Biotech Values

[DewDiligence]

GILD—Others should voice their opinion.

You seem to be willing to accept the sell-side projections for GILD’s HIV franchise—lock, stock, and barrel; however, if something should go wrong with the TAF program, those numbers won’t hold up.

According to GILD’s presentation at Cowen this week, there will be eight TAF studies to report data during 2014; if all goes well, GILD hopes to submit an NDA/MAA for a TAF-based HIV regimen in 2015.